Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2015 ASCO Annual Meeting /
Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyosarcoma

29th May - 2nd Jun 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.15
Views: 2259
Rating:

Prof Gary Schwartz - Columbia University, New York, USA

Dr Schwartz gives an expert commentary on data presented at ASCO 2015. 

452 patients with advanced leiomyosarcoma or adipocytic sarcoma, which is also called liposarcoma, were randomly assigned to treatment with eribulin or dacarbazine until disease progression.

The median overall survival was 13.5 months in the eribulin group and 11.5 months in the dacarbazine group.

Dr Schwartz looks at the implications of this and gives some background on the difficulty of treating sarcomas.

Read the news story for more.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation